Request Demo

Last update 15 May 2025

I-131-Apamistamab

Last update 15 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Radiolabeled antibody, Therapeutic radiopharmaceuticals

Synonyms

131 I-Apamistamab, 131-I-labeled anti-CD45 antibody, 131-I-labeled BC8 antibody

+ [14]

Target

CD45

Action

inhibitors

Mechanism

CD45 inhibitors(Leukocyte common antigen inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases

Active Indication

Refractory acute myeloid leukemiaRelapsing acute myeloid leukemiaDiffuse large B-cell lymphoma recurrent+ [1]

Inactive Indication-

Originator Organization

Fred Hutchinson Cancer Research Center

Active Organization

Actinium Pharmaceuticals, Inc.

The University of Texas Southwestern Medical Center

Inactive Organization-

License Organization

Immedica Pharma AB

Actinium Pharmaceuticals, Inc.

University of California, Davis

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Boost your research with our ADC technology data.

view full example data

Sequence Code 616719846H

Source: *****

Sequence Code 616719847L

Source: *****

Clinical Trials associated with I-131-Apamistamab

NCT06768905

/ RecruitingPhase 1/2IIT

IOMAB-ACT: A Phase Ib/II Multi-institutional Study of 131 I-Apamistamab Followed by CD19-Targeted CAR-T Cell Therapy for Patients With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).

Start Date25 Apr 2025

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

[+1]

NCT04512716

/ RecruitingEarly Phase 1IIT

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

Start Date02 Feb 2021

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

NCT02665065

/ Active, not recruitingPhase 3

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).

Start Date01 Jun 2016

Sponsor / Collaborator

Actinium Pharmaceuticals, Inc.

100 Clinical Results associated with I-131-Apamistamab

100 Translational Medicine associated with I-131-Apamistamab

100 Patents (Medical) associated with I-131-Apamistamab

Literatures (Medical) associated with I-131-Apamistamab

10 Jan 2025·JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III SIERRA Trial of ¹³¹ I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

Article

Author: Pandit-Taskar, Neeta ; Schuster, Michael ; Abboud, Camille ; Foran, James ; Larkin, Karilyn ; Reddy, Vijay ; Lazarus, Hillard M. ; Koshy, Nebu ; Jamieson, Katarzyna ; Choe, Hannah ; Haeuber, Elaina ; Law, Arjun Datt ; Gyurkocza, Boglarka ; Litzow, Mark R. ; Rowley, Scott D. ; Tomlinson, Benjamin ; Silverman, Margarida ; Seropian, Stuart ; Orozco, Johnnie J. ; McNamara, Kathleen ; MacDougall, James ; Sandmaier, Brenda M. ; Desai, Avinash ; Pagel, John M. ; Spross, Jennifer ; Levy, Moshe Y. ; Munshi, Pashna ; Sabloff, Mitchell ; Hari, Parameswaran ; Cook, Rachel ; Van Besien, Koen ; Stiff, Patrick ; Kebriaei, Partow ; Giralt, Sergio ; Abhyankar, Sunil ; Vusirikala, Madhuri ; Nahar, Akash ; Chen, George ; Al-Kadhimi, Zaid ; Nath, Rajneesh

PURPOSE:

Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131 I-apamistamab with conventional care.

METHODS:

SIERRA (ClinicalTrials.gov identifier: NCT02665065 ) was a phase III open-label trial. Patients age ≥55 years with active RR AML were randomly assigned 1:1 to either an 131 I-apamistamab–led regimen before alloHCT or conventional care followed by alloHCT if initial complete remission (CR)/CR with incomplete platelet recovery (CRp) occurred. Initial response was assessed 28-56 days after alloHCT in the 131 I-apamistamab group and 28-42 days after salvage chemotherapy initiation; patients without CR/CRp or with AML progression could cross over to receive 131 I-apamistamab followed by alloHCT. The primary end point was durable complete remission (dCR) lasting 180 days after initial CR/CRp. Secondary end points were overall survival (OS) and event-free survival (EFS), assessed hierarchically in the intention-to-treat (ITT) population.

RESULTS:

The ITT population included 153 patients ( 131 I-apamistamab [n = 76]; conventional care [n = 77]). In total, 44/77 conventional care arm patients crossed over and 40/77 (52%) received 131 I-apamistamab and alloHCT, with six patients (13.6%) experiencing a dCR. In the ITT population, the dCR rate was significantly higher with 131 I-apamistamab (17.1% [95% CI, 9.4 to 27.5]) than conventional care (0% [95% CI, 0 to 4.7]; P < .0001). The OS hazard ratio (HR) was 0.99 (95% CI, 0.70 to 1.41; P = .96), and the EFS HR was 0.23 (95% CI, 0.15 to 0.34), with HR <1 favoring 131 I-apamistamab. Grade ≥3 treatment-related adverse events occurred in 59.7% and 59.2% of the 131 I-apamistamab and conventional care groups, respectively.

CONCLUSION:

The 131 I-apamistamab–led regimen was associated with a higher dCR rate than conventional care in older patients with RR AML. 131 I-apamistamab was well tolerated and could address an unmet need in this population.

04 Jun 2009·BloodQ1 · MEDICINE

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma

Q1 · MEDICINE

Article

Author: Press, Oliver W. ; Fromm, Jonathan R. ; Gopal, Ajay K. ; Pagel, John M. ; Wilbur, Shani

Abstract:

Radioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) are limited. We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL. CD45 was highly expressed on hT-NHL patient samples (median, 2.3 × 105 antigen-binding capacity units/cell) and hT-NHL cell lines (3.4 × 105 CD45 antigen-binding capacity units/cell). Biodistribution studies in hTNHL xenografts showed that 131I-labeled BC8 (anti-hCD45) delivered 154% (P = .01) and 237% (P = .002) more radioiodine to tumor sites over control antibodies at 24 hours and 48 hours, respectively. Importantly, tumor sites targeted with 131I-BC8 exhibited 2.5-fold (P = .05), 3.0-fold (P = .007), and 3.6-fold (P = .07) higher 131I retention over the nontarget organs of lungs, liver, and kidneys, respectively (24 hours). Because the clinical use of anti-hCD45 would target both T-NHL and other hematolymphoid tissues, we evaluated the ability of anti-mCD45 to target mT-NHL. mT-NHL grafts targeted with anti-mCD45 correspondingly retained 5.3 (P < .001), 5.4 (P < .001), and 8.7 (P < .001) times the radioactivity in tumor sites compared with nontarget organs of lung, liver, and kidney. 131I-labeled BC8 therapy yielded improved complete remission rates (75% vs 0%, P < .001) and progression-free survivals (median, 23 days vs 4.5 days, P < .001) compared with controls. These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients.

01 Oct 2006·Indian journal of experimental biology

Heat stress induced apoptosis in BC-8 cells derived from AK-5 tumor involves downregulation of Bcl-2 and generation of reactive oxygen species.

Article

Author: Pardhasaradhi, B V V ; Kumari, A Leela ; Rangaraj, Nandini ; Khar, Ashok ; Varalakshmi, Ch

BC-8, a rat histiocytoma undergoes apoptosis after heat shock, which is due to lack of an effective heat shock response. Heat shock induced generation of free radicals, which in turn are involved in the induction of apoptotic death in BC-8 cells. Treatment of BC-8 cells with N-acetylcysteine partially inhibited the heat induced apoptosis. Introduction of Bcl-2 gene in these cells did not protect them from apoptotic death, whereas transfection with hsp-70 gene did render these cells resistant to heat induced apoptosis transiently. Heat shock also downregulated the expression of Bcl-2 and p53 in these cells. These observations suggested that the heat shock induced apoptosis was mediated through reactive oxygen species and controlled upstream of Bcl-2 check point.

News (Medical) associated with I-131-Apamistamab

06 May 2025

·www.prnewswire.com

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy - Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK, May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioning agent intended to replace non-targeted chemotherapeutic conditioning agents such as Fludarabine and Cyclophosphamide (Flu/Cy) to address serious CAR-T related toxicities including immune effector cell-associated neurotoxicity (ICANS) and cytokine release syndrome (CRS), to potentially improve patient access and outcomes. Currently, there are seven CAR-T therapies approved for certain leukemias and lymphomas and multiple myeloma, that over 150,000 patients are diagnosed with annually. In 2024, the seven approved CAR-T therapies generated over $4 billion in sales and CAR-T therapies are forecasted to reach $12 billion in annual sales in 2030. Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at UTSW said, "We are thrilled to initiate patient enrollment to study Iomab-ACT targeted radiotherapy conditioning with a commercial CAR-T therapy. Iomab-ACT is supported by compelling preclinical and clinical data, and we believe it has immense potential to eliminate the need for chemotherapy-based conditioning, which is a major barrier for many patients seeking CAR-T treatment. Despite the positive impact CAR-T therapy has had on patient outcomes, there is still significant room for improvement. We are optimistic that Iomab-ACT can transform CAR-T therapy conditioning if this trial demonstrates it has the ability to increase patients access and reduce the rates and severity of ICANS and CRS and also potentially improve patient outcomes. We are excited to begin treating patients with Iomab-ACT and eager to present our preliminary findings later this year." Iomab-ACT targets CD45, a cell surface marker expressed on immune cells relevant to CAR-T therapy including lymphocytes and is the only clinical stage conditioning agent targeting CD45. Preclinical data demonstrated that Iomab-ACT can selectively target immune cells implicated in CAR-T toxicities, while sparing bone marrow stem cells, red blood cells and platelets. Preclinical and clinical data also showed that Iomab-ACT produces transient lymphodepletion that aligns with the CAR-T treatment process. This data supported the first clinical trial of Iomab-ACT with a novel CD19 CAR-T therapy in collaboration with Memorial Sloan Kettering Cancer Center (MSK) in patients heavily pretreated with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) or Diffuse Large B-cell Lymphoma (DLBCL). In this study, no patients (0/4) developed ICANS of any grade, and minimal CRS. Iomab-ACT also demonstrated transient depletion of peripheral blood lymphocytes and monocytes, persistence of CAR T-cells up to 8 weeks and minimal non-hematologic toxicities. These positive findings supported the continued advancement of Iomab-ACT and the initiation of the commercial CAR-T trial at UTSW. Sandesh Seth, Actinium's Chairman and CEO, stated, "This is a pivotal moment for our Iomab-ACT CD45 targeted radiotherapy conditioning program. Iomab-ACT is a highly differentiated conditioning agent that has produced promising initial clinical results where multiple targeted conditioning approaches including monoclonal antibodies and antibody drug conjugates directed against a variety of targets have not achieved clinical success to date. Based on the promising initial outcomes from the pilot study of Iomab-ACT with a novel CD19 CAR-T, we are incredibly excited by the potential of this commercial CAR-T trial and future development path. With initial clinical data expected beginning in the second half of this year, we are making strong progress to achieving our goal of establishing Iomab-ACT as a universal targeted conditioning regimen for CAR-T and other cellular therapies." Targeted Radiotherapy CAR-T Conditioning Opportunity A multi-billion-dollar market opportunity exists for better conditioning in other areas of cellular therapy, such as CAR-T. Currently, there are seven CAR T-cell therapies targeting CD19 for lymphoma and leukemia and BCMA for multiple myeloma that are approved by the FDA with total sales of over $4.0 billion in 2024. The pipeline of CAR-T therapies in development has rapidly expanded, with the addressable patient population expected to nearly double and reach approximately 93,000 patients in the U.S. by 2030 based on the current pipeline of cellular therapies. The addressable market for Iomab-ACT is in line with the patient population for cellular therapies that is approximately150,000 patients annually across the indications in which CAR-T therapies are approved, as all patients receive conditioning of some type. We believe a potential blockbuster revenue opportunity exists for Iomab-ACT assuming it can provide clinical benefits related to adverse events related to CAR-T, longer duration of response or improved survival outcomes. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. ATNM-400 is Actinium's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data demonstrating higher efficacy than Pluvicto (PSMA-617-Lutetium-177) and potent efficacy in Pluvicto resistant prostate cancer models. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. For more information, please visit: Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyCell TherapyClinical Study

14 Apr 2025

·www.prnewswire.com

ATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B According to the complaint, during the class period, defendants misled investors to believe there was a very high likelihood that the FDA would review and approve the Company's Biologics License Application ("BLA") for Iomab-B. The complaint alleges that defendants (i) repeatedly touted the Sierra Trial's positive DCR data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming the FDA had blessed the design of the trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the BLA. On August 5, 2024, Actinium announced "the FDA has now determined that the analyses from the Sierra trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study." On this new, the price of Actinium's common stock fell $3.69, or approximately to 60%, to close at $2.48 on August 5, 2024. What Now: You may be eligible to participate in the class action against Actinium Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 26, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Actinium Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Patent Infringement

28 Mar 2025

·www.prnewswire.com

Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO, March 28, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B According to the complaint, during the class period, defendants misled investors to believe there was a very high likelihood that the FDA would review and approve the Company's Biologics License Application ("BLA") for Iomab-B. The complaint alleges that defendants (i) repeatedly touted the Sierra Trial's positive DCR data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming the FDA had blessed the design of the trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the BLA. On August 5, 2024, Actinium announced "the FDA has now determined that the analyses from the Sierra trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study." On this new, the price of Actinium's common stock fell $3.69, or approximately to 60%, to close at $2.48 on August 5, 2024. What Now: You may be eligible to participate in the class action against Actinium Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 26, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Actinium Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Patent Infringement

100 Deals associated with I-131-Apamistamab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory acute myeloid leukemia	Phase 3	United States	Actinium Pharmaceuticals, Inc.	01 Jun 2016
Refractory acute myeloid leukemia	Phase 3	Canada	Actinium Pharmaceuticals, Inc.	01 Jun 2016
Relapsing acute myeloid leukemia	Phase 3	United States	Actinium Pharmaceuticals, Inc.	01 Jun 2016
Relapsing acute myeloid leukemia	Phase 3	Canada	Actinium Pharmaceuticals, Inc.	01 Jun 2016
Diffuse large B-cell lymphoma recurrent	Phase 2	United States	The University of Texas Southwestern Medical Center	25 Apr 2025
Diffuse large B-cell lymphoma recurrent	Phase 2	United States	Actinium Pharmaceuticals, Inc.	25 Apr 2025
Diffuse large B-cell lymphoma refractory	Phase 2	United States	Actinium Pharmaceuticals, Inc.	25 Apr 2025
Diffuse large B-cell lymphoma refractory	Phase 2	United States	The University of Texas Southwestern Medical Center	25 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	-	-	Iomab-B	tlqtkpotbk(xskhbkpndr) = zsfxwvsilx vhpzejbwoq (ccppdkwmko )	-	09 Jun 2024
NCT02665065 (SIERRA, EHA2024) Manual	Phase 3	Acute Myeloid Leukemia TP53 Mutation	153	Iomab-B with fludarabine and total body irradiation	epzimadhhx(oyzceejssw) = ckupajmsyc aezusuluqd (moivocartd ) View more	Positive	14 May 2024
				131I-APAMISTAMAB-LED (Conventional Care)	epzimadhhx(oyzceejssw) = vhvikpjdcw aezusuluqd (moivocartd ) View more
NCT02665065 (SIERRA, EHA2024) Manual	Phase 3	Acute Myeloid Leukemia CD45	153	Iomab-B with fludarabine and total body irradiation (2 Gy) followed by HCT	vukvvgxrdn(lyxgjyofhp) = foyejqphyv hfemmwwzif (qdexacdnkl ) View more	Positive	14 May 2024
				131I-APAMISTAMAB-LED (Physician’s choice of conventional care (CC))	vukvvgxrdn(lyxgjyofhp) = nheafruvfs hfemmwwzif (qdexacdnkl ) View more
NCT02665065 (SIERRA, EBMT2024) Manual	Phase 3	Acute Myeloid Leukemia TP53 Mutation	153	Iomab-B	nkcdgxwwuq(wjaoepcgpx) = mbhktntvno whacxkgeot (ynzfhdztwr )	Positive	17 Apr 2024
NCT02665065 (SIERRA, Biospace) Manual	Phase 3	Acute Myeloid Leukemia TP53 Mutation	54	Iomab-B	rxwnxwdnpq(bfjtolvmwu) = jevzjflvoc pofakegage (feqoolzyan ) View more	Positive	26 Feb 2024
				Crossover	rxwnxwdnpq(bfjtolvmwu) = axeaobfyxh pofakegage (feqoolzyan ) View more
NCT02665065 (SIERRA, Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 3	Acute Myeloid Leukemia TP53 Mutation	153	Iomab-B with fludarabine and total body irradiation	ozqijqmmgt(mzzkyyrdrl) = imifysyxaf wtmockgwhi (jedsrbpfmk ) View more	Positive	01 Feb 2024
				Apamistamab (Conventional Care)	ozqijqmmgt(mzzkyyrdrl) = xijheymuwh wtmockgwhi (jedsrbpfmk ) View more
NCT02665065 (SIERRA, Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 3	Acute Myeloid Leukemia CD45	153	Iomab-B with fludarabine and total body irradiation (2 Gy)	sgseircblu(mzkbhvjlal) = uvqicwrgod xdtjzewiyc (bzadmekgbt, 9.7 - 33.1) View more	Positive	01 Feb 2024
				I-Apamistamab (Conventional Care (CC))	sgseircblu(mzkbhvjlal) = ybcdilabvp xdtjzewiyc (bzadmekgbt ) View more
NCT02665065 (SIERRA, Biospace) Manual	Phase 3	Acute Myeloid Leukemia TP53 Mutation	153	Iomab-B (Crossover + TP53 Mutation)	qyuzeuogbe(npejvosyur) = kugbjenxhr zwpldszajn (wdkuzhzhgx ) View more	Positive	11 Dec 2023
				Control Arm (TP53 Mutation)	qyuzeuogbe(npejvosyur) = nvtbeapcqy zwpldszajn (wdkuzhzhgx ) View more
NCT02665065 (SIERRA, ASH2023)	Phase 3	Acute Myeloid Leukemia TP53 mutation positive	153	131I-apamistamab led induction and conditioning followed by alloHCT	zmkfacpfgd(yvhkvyjngd) = rvqgcfjpbu dkzhgadubf (botvqmodzh, 12.29 - 34.73) View more	Positive	10 Dec 2023
				physician’s choice of conventional care	sxmqqehkqx(wjbtwqdngq) = etxmxefpcg ysdxmndfpb (hirctjilhb )
NCT02665065 (SIERRA, ASH2023)	Phase 3	Acute Myeloid Leukemia	153	131I-apamistamab with fludarabine and total body irradiation	ouqrdocqzt(yiaoaygimm) = basnoegnep cpydrvwwkd (pumgsrcmfj, 11.5 - 22.3) View more	Positive	10 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis